Disclaimer: This site is intended for residents of the United States only. If you live outside of the US, for information on studies of olaparib in ovarian cancer please visit www.astrazenecaclinicaltrials.com and enter ‘olaparib’ in the search box.
Ovarian cancer is the ninth most common cancer in women (excluding non-aggressive skin cancers). During their lifetime, one out of 72 women will get ovarian cancer and it is the fifth most common cause of death from cancer in women. Treatment of ovarian cancer usually involves a combination of surgery and chemotherapy. Although 80% of women will respond to chemotherapy, most will experience relapse at some time so scientists are searching for new medicines to fight this disease.
AstraZeneca is committed to ovarian cancer research to help find effective treatments for this disease. We have recently started two new ovarian cancer studies (also known as clinical trials) involving women around the world with BRCA-positive ovarian cancer. The studies are called SOLO1 and SOLO2. The SOLO1 study will involve women with newly diagnosed ovarian cancer, whereas the SOLO2 study will include patients who have previously been diagnosed and treated for ovarian cancer and now the disease has come back; this is termed ‘relapsed’ or ‘recurrent’ ovarian cancer.
The goal of the SOLO studies is to determine if a potential new medicine (otherwise known as an ‘investigational therapy’) called olaparib could be a successful treatment for specific types of ovarian cancer in the future. This website provides information about the SOLO clinical trials for patients who may be interested in taking part, as well as information for their families, caregivers, and healthcare professionals.